| Large Cell Neuroendocrine Carcinoma studied in …STUDIED_INderived24 of 24show fewer |
|---|
| → studied in | NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (16 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04079712Phase 2 · active not recruiting Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors · condition mapped CURATED_BROADER · 24 trials mapped (16 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07006727Phase 1 · recruiting Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07278479Phase 1/Phase 2 · recruiting Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (16 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176989Phase 2 · recruiting Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors · condition mapped CURATED_BROADER · 24 trials mapped (16 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07080242Phase 1 · recruiting Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors · condition mapped CURATED_BROADER · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04723095recruiting Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix · condition mapped ONTOLOGY_EXACT · 24 trials mapped (16 active) | — | — | Cervical Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07561645Phase 2 · not yet recruiting A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03728361Phase 2 · completed Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (16 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05652686Phase 1/Phase 2 · recruiting A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06049966Phase 1 · completed Atezolizumab in Large Cell Neuroendocrine Carcinoma · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04010357Phase 2 · completed Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06736418Phase 1 · active not recruiting Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05470595Phase 2 · active not recruiting A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07510594Phase 2 · not yet recruiting A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05680922Phase 1 · active not recruiting DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393816Phase 2 · recruiting FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06418087Phase 2 · recruiting Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04452292NA · completed Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma · condition mapped ONTOLOGY_EXACT · 24 trials mapped (16 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03901378Phase 2 · withdrawn Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02709889Phase 1/Phase 2 · terminated Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 24 trials mapped (16 active) | — | — | Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02755675Phase 2 · unknown uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02943798Phase 2 · unknown Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma · condition mapped ALIAS · 24 trials mapped (16 active) | — | — | Lung Large Cell Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |